Shares of Danish drugmaker Novo Nordisk A/S (NVO) surged over 5% in pre-market trading on Friday following the company's announcement of positive topline results from a Phase 1b/2a clinical trial evaluating its investigational obesity drug amycretin.
The early-stage trial evaluated the safety, tolerability, and weight loss efficacy of once-weekly subcutaneous injections of amycretin, a novel unimolecular GLP-1 and amylin receptor agonist, in 125 individuals with overweight or obesity.
The results showed that amycretin exhibited a favorable safety profile consistent with other incretin-based therapies. More importantly, amycretin led to significant and dose-dependent weight loss, with patients in the highest 20mg dose group achieving an estimated 22% reduction in body weight over 36 weeks of treatment. In comparison, the placebo group experienced only a 2% weight gain over the same period.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。